Retatrutide is a triple agonist peptide representing the cutting edge of weight loss research. It targets GLP-1, GIP, and glucagon receptors simultaneously, showing remarkable results in clinical trials for weight reduction.
Triple agonist targeting GLP-1 (appetite/insulin), GIP (metabolic efficiency), and glucagon (fat burning) receptors for synergistic metabolic effects.
Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
This peptide is primarily sold as a research-only compound in lyophilized powder form. It is not approved for human use and is intended for laboratory research purposes only.
Fat metabolism support
Targeted fat reduction
Fat metabolism
Appetite regulation
Browse our verified directory of pharmacies, telehealth providers, and research vendors.
Browse ProvidersThe information provided about RETATRUTIDE is for educational and research purposes only. This content is not intended as medical advice, diagnosis, or treatment recommendation.RETATRUTIDE is a research compound and may not be approved for human use. Always consult with a qualified healthcare provider before considering any peptide therapy. The Peptide List does not sell peptides or provide medical services.
This website is for informational purposes only and does not constitute medical advice. Consult a licensed physician before using any peptides. Provider listings do not constitute endorsements. None of the statements on this site have been evaluated by the FDA.